GLYNASE Drug Patent Profile
✉ Email this page to a colleague
When do Glynase patents expire, and what generic alternatives are available?
Glynase is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in GLYNASE is glyburide. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the glyburide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Glynase
A generic version of GLYNASE was approved as glyburide by TEVA on August 29th, 1995.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GLYNASE?
- What are the global sales for GLYNASE?
- What is Average Wholesale Price for GLYNASE?
Summary for GLYNASE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 152 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,336 |
| Drug Prices: | Drug price information for GLYNASE |
| What excipients (inactive ingredients) are in GLYNASE? | GLYNASE excipients list |
| DailyMed Link: | GLYNASE at DailyMed |
Recent Clinical Trials for GLYNASE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Medical College of Wisconsin | Phase 4 |
| Texas Tech University Health Sciences Center, El Paso | Early Phase 1 |
| Takeda | Phase 4 |
US Patents and Regulatory Information for GLYNASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-001 | Mar 4, 1992 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-004 | Sep 24, 1993 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-002 | Mar 4, 1992 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-003 | Sep 24, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GLYNASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-004 | Sep 24, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-003 | Sep 24, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-002 | Mar 4, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-001 | Mar 4, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-001 | Mar 4, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | GLYNASE | glyburide | TABLET;ORAL | 020051-001 | Mar 4, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for GLYNASE
See the table below for patents covering GLYNASE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Belgium | 684654 | ⤷ Sign Up | |
| Brazil | 6685071 | ⤷ Sign Up | |
| Austria | 275541 | ⤷ Sign Up | |
| Monaco | 601 | ⤷ Sign Up | |
| Switzerland | 513139 | Verfahren zur Herstellung von neuen Benzolsulfonylharnstoffen | ⤷ Sign Up |
| Spain | 355477 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
